The return to normal operations within the US Food and Drug Administration'sCenter for Biologics Evaluation and Research next year will require eliminating backlogs and resuming regular meeting schedules.
CBER director Peter Marks said the center’s theme for the remainder of 2022 is response and recovery as it tries...







